Patent number: 7105524
Abstract: Di- and trifluorosubstituted alkene compounds of formula I wherein X is hydrogen or fluorine; Y is oxygen, NR1 or S(O)m; R1 is hydrogen or C1–C6-alkyl; m is 0, 1, or 2; A,B,D and E are selected from the following: a) A is N and B, D and E are CR2; or b) B is N and A, D and E are CR2; or c) D is N and A, B, and E are CR2; or d) A and D are N and B and E are CR2; or e) B and E are N and A and D are CR2; R2 is H, halogen, NH2, NO2, CN, alkyl, haloalkyl, alkenyl, alkoxy, haloalkoxy, alkylthio, haloalkylthio, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, aminosulfonyl, alkoxyalkyl, alkylthioalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl,alkylaminoalkyl, dialkylaminoalkyl, hydroxycarbonyl, or alkoxycarbonyl; or phenyl which may be substituted with halogen, CN, NO2, alkyl, haloalkyl, alkoxy, or haloalkoxy; or a 5- to 6-membered heteroaromatic ring system containing 1 to 3 heteroatoms selected from oxygen, sulfur and nitrogen, which may be substituted with halogen, CN, NO2, alkyl, haloa
Type:
Grant
Filed:
September 9, 2002
Date of Patent:
September 12, 2006
Assignee:
BASF Aktiengesellschaft
Inventors:
William Wakefield Wood, David Kuhn, Yulin Hu, Berhane Tecle
Patent number: 6841549
Abstract: The present invention provides a preventive or therapeutic agent for diabetes mellitus and diabetic complications, which is a new type based on an adenosine A2 receptor antagonist action. That is, it provides a novel condensed imidazole compound which has an adenosine A2 receptor antagonist action, is effective for preventing or treating diabetes mellitus and diabetic complications, and is represented by the formula (I); (wherein R1 represents e.g. an amino group which may be substituted with an alkyl group; R2 represents e.g. hydrogen atom, an alkyl group, a cycloalkyl group or an alkyl group, alkenyl group or alkynyl group which may be substituted with hydrox etc.; R3 represents e.g. an optionally substituted alkyl group, alkenyl group, alkynyl group, aryl group, heteroaryl group, pyridinone group, pyrimidinone group or piperadinone group; Ar represents e.g.
Type:
Grant
Filed:
June 30, 2000
Date of Patent:
January 11, 2005
Assignee:
Eisai Co., Ltd.
Inventors:
Osamu Asano, Hitoshi Harada, Seiji Yoshikawa, Nobuhisa Watanabe, Takashi Inoue, Tatsuo Horizoe, Nobuyuki Yasuda, Kaya Ohashi, Hiroe Minami, Junsaku Nagaoka, Manabu Murakami, Seiichi Kobayashi, Isao Tanaka, Tsutomu Kawata, Naoyuki Shimomura, Hiroshi Akamatsu, Naoki Ozeki, Toshikazu Shimizu, Kenji Hayashi, Toyokazu Haga, Shigeto Negi, Toshihiko Naito
Publication number: 20040266793
Abstract: The invention relates to a pyrimidone derivative represented by formula (I) or a salt thereof wherein: X represents two hydrogen atoms, a sulphur atom, an oxygen atom or a C1-2 alkyl group and a hydrogen atom; y represents a bond, an ethenylene group, an ethynylene group, an oxygen atom, a sulphur atom, a sulfonyl group, a sulfoxide group, a carbonyl group, a nitrogen atom being optionally; or a methylene group optionally substituted; R1 represents a pyrimidine group optionally substituted; R2 may represent a C1-6 alkyl group optionally substituted by a C6,10 aryloxy or a C6,10 arylamino group; a C3-6 cycloalkyl group, a C1-4 alkylthio group, a C1-4 alkoxy group, a C1-2 perhalogenated alkyl group, a C1-3 halogenated alkyl group, a phenylthio group, a benzyl group, a benzene ring, an indan ring, a 5,6,7,8-tetrahydronaphthalene ring, a naphthalene ring, a pyridine ring, a pyrrole ring, a thiophene ring, a furan ring or an imidazole ring; R3 and R4 represents each independently a hydrogen atom, C1-6 alkyl group,
Type:
Application
Filed:
August 11, 2004
Publication date:
December 30, 2004
Inventors:
Thierry Gallet, Patrick Lardenois, Alistair Lochead, Severine Marguerie, Alain Nedelec, Mourad Saady, Franck Slowinski, Philippe Yaiche